Cargando…

Acute liver injury in a Glatopa-treated patient with MS

Detalles Bibliográficos
Autores principales:	Sabatino, Joseph J., Mehta, Neil J., Kakar, Sanjay, Zamvil, Scott S., Cree, Bruce A.C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459788/ https://www.ncbi.nlm.nih.gov/pubmed/28626784 http://dx.doi.org/10.1212/NXI.0000000000000368

Ejemplares similares

Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?
por: Maguire, Cole, et al.
Publicado: (2020)

Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody–positive encephalitis
por: Orengo, James P., et al.
Publicado: (2015)

pRNFL as a marker of disability worsening in the medium/long term in patients with MS
por: Cordano, Christian, et al.
Publicado: (2018)

Equivalent Gene Expression Profiles between Glatopa(™) and Copaxone(®)
por: D’Alessandro, Josephine S., et al.
Publicado: (2015)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report
por: Shirani, Afsaneh, et al.
Publicado: (2021)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

HSV-2–related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS
por: Ikumi, Kazuhiro, et al.
Publicado: (2016)

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab
por: Pawlitzki, Marc, et al.
Publicado: (2018)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Unique invariant CD8(+) T cell population persists in MS
por: Sabatino, Joseph J., et al.
Publicado: (2015)

Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS
por: Mehling, Matthias, et al.
Publicado: (2014)

Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activity
por: Sabatino, Joseph J., et al.
Publicado: (2017)

Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19
por: Fuchs, Vidmante, et al.
Publicado: (2021)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Epstein-Barr–negative MS: a true phenomenon?
por: Dobson, Ruth, et al.
Publicado: (2017)

Case of alemtuzumab-related alopecia areata management in MS
por: Chan, Jillian K., et al.
Publicado: (2018)

Longitudinally extensive myelitis in MS mimicking neuromyelitis optica
por: Whittam, Daniel, et al.
Publicado: (2017)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

COVID-19 in MS: Initial observations from the Pacific Northwest
por: Bowen, James D., et al.
Publicado: (2020)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

Lipoic Acid Pharmacokinetics at Baseline and 1 year in Secondary Progressive MS
por: Bittner, Frank, et al.
Publicado: (2017)

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS
por: Harris, Sarah, et al.
Publicado: (2020)

Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod
por: Okada, Kazumasa, et al.
Publicado: (2018)

Gut bacteria Akkermansia elicit a specific IgG response in CSF of patients with MS
por: Vallino, Amélie, et al.
Publicado: (2020)

Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS
por: Torkildsen, Øivind, et al.
Publicado: (2014)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

IgA autoantibodies against native myelin basic protein in a patient with MS
por: Schumacher, Heike, et al.
Publicado: (2019)

ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports
por: Körtvélyessy, Peter, et al.
Publicado: (2017)

Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient
por: Massey, Thomas H., et al.
Publicado: (2017)

Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS
por: Novi, Giovanni, et al.
Publicado: (2020)

Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate
por: Ma, Brandy B., et al.
Publicado: (2016)

Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis
por: Bell, Christine, et al.
Publicado: (2017)

Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg
por: Turner, Lindsey E., et al.
Publicado: (2019)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Fatal TTR amyloidosis with neuropathy from domino liver p.Val71Ala transplant
por: Puffer, Ross C., et al.
Publicado: (2019)

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
por: Spencer, Collin M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lpo7ln4p9rlvd6cplsv7hhungq